Hanne Kobberø
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanne Kobberø has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Mads Hvid Poulsen
Department for Urology, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark, 6700 Esbjerg, Denmark
4 shared publications - Torben Brøchner Pedersen
Department of Urology, Odense University Hospital, Odense, Denmark
3 shared publications Jan Krhut
Department of Urology, University Hospital, Ostrava, Czech Republic
2 shared publications- Karin Andersen
Department of Urology, Odense University Hospital, Odense, Denmark
2 shared publications Mikkel Fode
Department of Urology, Copenhagen University Hospital ‐ Herlev and Gentofte Hospital, Herlev, Denmark
2 shared publicationsPeter Zvara
Department of Urology, Odense University Hospital, Odense, Denmark
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Springer Nature in Trials
Efficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial
Background: Multiple sclerosis (MS) is frequently accompanied by neurogenic lower urinary tract dysfunction (NLUTD). Sacral neuromodulation (SNM) is a guideline-endorsed therapy for refractory urinary symptoms, but evidence in NLUTD remains limited. We aim to provide robust efficacy data. Methods: Since August 2023, this multicenter, placebo-controlled, double-blind, superiority, randomized trial has enrolled adults with MS and NLUTD refractory to guideline-endorsed therapies. All participants undergo a 1-month test phase with a tined lead and external stimulator, and responders (≥ 50% improvement in at least one group-specific bladder diary variable) receive an implantable pulse generator (IPG). After a 1-month optimization period, participants are randomized 1:1 to active (IPG ON) or placebo (IPG OFF) treatment for 4 months. Blinding is maintained through subsensory stimulation. Bladder diaries and questionnaires are collected at baseline, post-test phase, after optimization, midterm, and study end (total duration 6 months). Urodynamics are performed at baseline and at study end. The primary objective is to determine whether continuous SNM is more effective than placebo in sustaining symptom improvement over time. The primary outcome is the proportion of participants with a confirmed response at randomization (C) who, 4 months after randomization (E), still show ≥ 50% improvement from baseline in at least one group-specific bladder diary variable. The proportions maintaining this response are compared between the IPG ON and IPG OFF groups. Secondary outcomes include changes in bladder, bowel, and sexual function (ICIQ), health-related quality of life (EQ-5D-5L), treatment satisfaction (Global Assessment Score, GAS), urodynamic measures, safety monitoring, and effective stimulation parameters. The primary outcome will be analyzed by logistic regression and continuous secondary outcomes by linear mixed models; subgroup analyses are exploratory. Assuming success rates of 0.5 (SNM) versus 0.15 (control), 27 patients per group are required (power 0.8, α = 0.05); 30 per group will be randomized (approximately 86 enrolled) to allow for dropouts. Discussion: This trial will provide high-quality evidence on SNM in a well-defined MS cohort and may help refine patient selection and define the role of SNM in the management of lower urinary tract dysfunction. Trial registration: ClinicalTrials.gov NCT05380856. Registered on 19 May 2022.
- 7 November 2026
- Published by Springer Nature in Trials
Open AccessEfficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial
Background: Multiple sclerosis (MS) is frequently accompanied by neurogenic lower urinary tract dysfunction (NLUTD). Sacral neuromodulation (SNM) is a guideline-endorsed therapy for refractory urinary symptoms, but evidence in NLUTD remains limited. We aim to provide robust efficacy data. Methods: Since August 2023, this multicenter, placebo-controlled, double-blind, superiority, randomized trial has enrolled adults with MS and NLUTD refractory to guideline-endorsed therapies. All participants undergo a 1-month test phase with a tined lead and external stimulator, and responders (≥ 50% improvement in at least one group-specific bladder diary variable) receive an implantable pulse generator (IPG). After a 1-month optimization period, participants are randomized 1:1 to active (IPG ON) or placebo (IPG OFF) treatment for 4 months. Blinding is maintained through subsensory stimulation. Bladder diaries and questionnaires are collected at baseline, post-test phase, after optimization, midterm, and study end (total duration 6 months). Urodynamics are performed at baseline and at study end. The primary objective is to determine whether continuous SNM is more effective than placebo in sustaining symptom improvement over time. The primary outcome is the proportion of participants with a confirmed response at randomization (C) who, 4 months after randomization (E), still show ≥ 50% improvement from baseline in at least one group-specific bladder diary variable. The proportions maintaining this response are compared between the IPG ON and IPG OFF groups. Secondary outcomes include changes in bladder, bowel, and sexual function (ICIQ), health-related quality of life (EQ-5D-5L), treatment satisfaction (Global Assessment Score, GAS), urodynamic measures, safety monitoring, and effective stimulation parameters. The primary outcome will be analyzed by logistic regression and continuous secondary outcomes by linear mixed models; subgroup analyses are exploratory. Assuming success rates of 0.5 (SNM) versus 0.15 (control), 27 patients per group are required (power 0.8, α = 0.05); 30 per group will be randomized (approximately 86 enrolled) to allow for dropouts. Discussion: This trial will provide high-quality evidence on SNM in a well-defined MS cohort and may help refine patient selection and define the role of SNM in the management of lower urinary tract dysfunction. Trial registration: ClinicalTrials.gov NCT05380856. Registered on 19 May 2022.
- Open Access
- 5 October 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-9
Sacral nerve modulation for urinary disorders
Overactive bladder and non-obstructive urinary retention are highly prevalent urological conditions with substantial impact on patients’ quality of life. Following comprehensive clinical evaluation, sacral nerve modulation (SNM) may be considered in patients with insufficient response to first- and second-line therapies. SNM is a minimally invasive, reversible therapy which modulates signaling in the sacral nerve roots restoring bladder and pelvic floor function. The therapy has demonstrated durable efficacy and safety. Optimal outcomes with SNM depend on careful patient selection in a multidisciplinary setting, as argued in this review.
- 5 October 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-9
Open AccessSacral nerve modulation for urinary disorders
Overactive bladder and non-obstructive urinary retention are highly prevalent urological conditions with substantial impact on patients’ quality of life. Following comprehensive clinical evaluation, sacral nerve modulation (SNM) may be considered in patients with insufficient response to first- and second-line therapies. SNM is a minimally invasive, reversible therapy which modulates signaling in the sacral nerve roots restoring bladder and pelvic floor function. The therapy has demonstrated durable efficacy and safety. Optimal outcomes with SNM depend on careful patient selection in a multidisciplinary setting, as argued in this review.
- Open Access
- 14 April 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (5) , 1109-1119
Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction in Patients With Multiple Sclerosis: A Pilot Trial
Aims: We present results of a two‐arm pilot study assessing the feasibility of conducting a double‐blind randomized controlled trial (RCT) to evaluate the efficacy of sacral neuromodulation (SNM) in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).Methods: Eligible subjects with refractory NLUTD and EDSS < 5 underwent SNM test phase. Those showing more than a 50% improvement of bladder variables, received implantable pulse generators (IPG) and were randomized to either treatment group (IPG ON) or to sham group (IPG OFF) for 1 month. During second month, all patients had the IPG ON until the end of the trial. The primary endpoints were trial feasibility, recruitment potential, and response rate at the end of SNM test phase. Secondary endpoint was safety. Changes in key bladder diary‐derived variables and patient reported outcomes were recorded as well.Results: Thirty‐two patients were screened, 17 were eligible and 13 were included in the SNM test phase. Eleven were considered responders and were implanted with IPG. Subsequently, six patients were randomized to the treatment group and five to the sham group. No serious adverse events were reported. In the intervention phase, both objective and subjective improvements were seen in the treatment group, while the symptoms in the sham group remained mostly unchanged. At study completion, six patients reported being completely satisfied, three were mostly satisfied, and two were indifferent to the treatment.Conclusions: This pilot trial demonstrated feasibility of double‐blind RCT assessing safety and efficacy of SNM in MS patients.Trial registration: ClinicalTrials. gov NCT05380856.
- 14 April 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (5) , 1109-1119
Open AccessSacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction in Patients With Multiple Sclerosis: A Pilot Trial
Aims: We present results of a two‐arm pilot study assessing the feasibility of conducting a double‐blind randomized controlled trial (RCT) to evaluate the efficacy of sacral neuromodulation (SNM) in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).Methods: Eligible subjects with refractory NLUTD and EDSS < 5 underwent SNM test phase. Those showing more than a 50% improvement of bladder variables, received implantable pulse generators (IPG) and were randomized to either treatment group (IPG ON) or to sham group (IPG OFF) for 1 month. During second month, all patients had the IPG ON until the end of the trial. The primary endpoints were trial feasibility, recruitment potential, and response rate at the end of SNM test phase. Secondary endpoint was safety. Changes in key bladder diary‐derived variables and patient reported outcomes were recorded as well.Results: Thirty‐two patients were screened, 17 were eligible and 13 were included in the SNM test phase. Eleven were considered responders and were implanted with IPG. Subsequently, six patients were randomized to the treatment group and five to the sham group. No serious adverse events were reported. In the intervention phase, both objective and subjective improvements were seen in the treatment group, while the symptoms in the sham group remained mostly unchanged. At study completion, six patients reported being completely satisfied, three were mostly satisfied, and two were indifferent to the treatment.Conclusions: This pilot trial demonstrated feasibility of double‐blind RCT assessing safety and efficacy of SNM in MS patients.Trial registration: ClinicalTrials. gov NCT05380856.
- 9 December 2024
- Published by Springer Nature in Nature Reviews Urology
- Vol. 22 (7) , 414-426
The mechanism of action of neuromodulation in the treatment of overactive bladder
Neuromodulation has been used in the treatment of various pelvic organ dysfunctions for almost 40 years and several placebo-controlled studies have confirmed its clinical effect. Many neuromodulation methods using different devices and stimulation parameters, targeting different neural structures have been introduced, but only a limited number have been adopted into routine clinical use. A substantial volume of basic research and clinical studies addressing specific effects of neuromodulation in the treatment of overactive bladder (OAB) have been published to date; however, their mechanistic implications have not been comprehensively summarized. Thus, our understanding of the mechanism of action of neuromodulation in OAB treatment is mainly based on postulated theories. Results from animal experiments suggest that different neuromodulation methods used to treat OAB share the same basic principles. The most likely explanation for the effect of neuromodulation in OAB therapy is the suppression of bladder afferent signalling, promotion of spinal guarding reflexes and modulation of non-specific supraspinal regulatory circuits.
- 9 December 2024
- Published by Springer Nature in Nature Reviews Urology
- Vol. 22 (7) , 414-426
The mechanism of action of neuromodulation in the treatment of overactive bladder
Neuromodulation has been used in the treatment of various pelvic organ dysfunctions for almost 40 years and several placebo-controlled studies have confirmed its clinical effect. Many neuromodulation methods using different devices and stimulation parameters, targeting different neural structures have been introduced, but only a limited number have been adopted into routine clinical use. A substantial volume of basic research and clinical studies addressing specific effects of neuromodulation in the treatment of overactive bladder (OAB) have been published to date; however, their mechanistic implications have not been comprehensively summarized. Thus, our understanding of the mechanism of action of neuromodulation in OAB treatment is mainly based on postulated theories. Results from animal experiments suggest that different neuromodulation methods used to treat OAB share the same basic principles. The most likely explanation for the effect of neuromodulation in OAB therapy is the suppression of bladder afferent signalling, promotion of spinal guarding reflexes and modulation of non-specific supraspinal regulatory circuits.
- 9 September 2022
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 56 (5-6) , 404-411
Implementation of sacral neuromodulation for urinary indications. A Danish prospective study during the initial 15 months of a new service in a tertiary referral hospital
Sacral neuromodulation (SNM) is a well-established treatment modality for idiopathic overactive bladder and urgency incontinence, idiopathic fecal incontinence and non-obstructive urinary retention...
- 9 September 2022
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 56 (5-6) , 404-411
Implementation of sacral neuromodulation for urinary indications. A Danish prospective study during the initial 15 months of a new service in a tertiary referral hospital
Sacral neuromodulation (SNM) is a well-established treatment modality for idiopathic overactive bladder and urgency incontinence, idiopathic fecal incontinence and non-obstructive urinary retention...
- 26 February 2021
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 55 (2) , 169-176
Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: a four-year follow-up single-centre experience
Overactive bladder (OAB) affects hundreds of millions of people worldwide and has significant detrimental effects on quality-of-life. Percutaneous tibial nerve stimulation (PTNS) is endorsed in the...
- 26 February 2021
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 55 (2) , 169-176
Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: a four-year follow-up single-centre experience
Overactive bladder (OAB) affects hundreds of millions of people worldwide and has significant detrimental effects on quality-of-life. Percutaneous tibial nerve stimulation (PTNS) is endorsed in the...
- Open Access
- 1 May 2020
- Published by Microbiology Society in Access Microbiology
- Vol. 2 (5) , e000108
Bacteraemia with Moryella indoligenes and Fastidiosipila sanguinis: a case report
Moryella indoligenes and Fastidiosipila sanguinis are obligate anaerobic Gram-positive bacteria that are rarely involved in human infections. We present the first case of bacteraemia with M. indoligenes , which was part of a co-infection with F. sanguinis . Both micro-organisms were identified by 16S rRNA gene sequencing and M. indoligenes was also identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Prostate cancer involving the bladder suggests that the urinary tract was the most likely primary site of infection.
- 1 May 2020
- Published by Microbiology Society in Access Microbiology
- Vol. 2 (5) , e000108
Open AccessBacteraemia with Moryella indoligenes and Fastidiosipila sanguinis: a case report
Moryella indoligenes and Fastidiosipila sanguinis are obligate anaerobic Gram-positive bacteria that are rarely involved in human infections. We present the first case of bacteraemia with M. indoligenes , which was part of a co-infection with F. sanguinis . Both micro-organisms were identified by 16S rRNA gene sequencing and M. indoligenes was also identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Prostate cancer involving the bladder suggests that the urinary tract was the most likely primary site of infection.